INT11034

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.18
First Reported 1987
Last Reported 2010
Negated 1
Speculated 0
Reported most in Abstract
Documents 23
Total Number 23
Disease Relevance 3.43
Pain Relevance 14.84

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Akr1d1) oxidoreductase activity (Akr1d1) cytoplasm (Akr1d1)
Anatomy Link Frequency
neurons 2
basal ganglia 2
nucleus accumbens 1
substantia nigra 1
prefrontal 1
Akr1d1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Dopamine 207 100.00 Very High Very High Very High
antagonist 74 100.00 Very High Very High Very High
agonist 54 100.00 Very High Very High Very High
dopamine receptor 48 100.00 Very High Very High Very High
substance P 8 100.00 Very High Very High Very High
withdrawal 15 99.48 Very High Very High Very High
narcan 8 98.76 Very High Very High Very High
Enkephalin 12 98.46 Very High Very High Very High
GABAergic 4 98.36 Very High Very High Very High
Morphine 32 98.08 Very High Very High Very High
Disease Link Frequency Relevance Heat
Schizophrenia 25 99.50 Very High Very High Very High
Generalized Anxiety Disorder 10 99.22 Very High Very High Very High
Depression 8 95.60 Very High Very High Very High
Urological Neuroanatomy 4 94.80 High High
Morphine Dependence 4 91.44 High High
Cognitive Disorder 4 91.44 High High
Pain 21 90.56 High High
Nociception 13 85.80 High High
Stroke 3 82.56 Quite High
Attention Deficit Hyperactivity Disorder 5 81.44 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Furthermore, the ability of dexamphetamine, primarily an indirect dopamine agonist, to excite striatal neurons in these anaesthetized animals suggests that stimulation of both D1 and D2 receptors is not abolished by anaesthesia.
Neg (not) Negative_regulation (abolished) of D1 in neurons associated with dopamine and agonist
1) Confidence 0.18 Published 1988 Journal Neuropharmacology Section Abstract Doc Link 3244408 Disease Relevance 0 Pain Relevance 0.25
Interestingly, SCH 23390, a selective blocker of D1 dopamine (DA) receptors which, given chronically to rats, induces a 32% increase in D1 receptor number and increases the Vmax of D1-stimulated striatal AC, resulted in marked resistance to acute morphine effects.
Negative_regulation (blocker) of D1 associated with dopamine and morphine
2) Confidence 0.14 Published 1989 Journal J. Neurosci. Res. Section Abstract Doc Link 2531233 Disease Relevance 0.08 Pain Relevance 0.63
In the substantia nigra, levels of immunoreactive dynorphin A and dynorphin B were increased after treatment with a D2-antagonist (sulpiride) and a D1-agonist (SKF 38393), while a D1-antagonist (SCH 23390) reduced levels.
Negative_regulation (reduced) of D1 in substantia nigra associated with dynorphin, antagonist, substantia nigra and agonist
3) Confidence 0.09 Published 1987 Journal Neuropharmacology Section Abstract Doc Link 2444900 Disease Relevance 0 Pain Relevance 1.11
Repeated treatment of rats with FNM for 6 days produced more than 80% inhibition of D2 dopamine receptors but less than 25% inhibition of D1 dopamine receptors.
Negative_regulation (inhibition) of D1 associated with dopamine receptor
4) Confidence 0.04 Published 1994 Journal Neurochem. Int. Section Abstract Doc Link 7820070 Disease Relevance 0 Pain Relevance 0.78
Strychnine and bicuculline usually had one of two different effects on the mIPSC decay time constant distributions; either selective decreases in the frequency of mIPSCs with decay times in certain classes (i.e., the D1 class was reduced by bicuculline, the D2 class by strychnine, and the D3 and D4 classes by both antagonists) or a nonselective depression in the frequency of mIPSCs with decay times in all four classes.
Negative_regulation (reduced) of D1 associated with depression and antagonist
5) Confidence 0.04 Published 1996 Journal J. Neurophysiol. Section Abstract Doc Link 8836236 Disease Relevance 0.10 Pain Relevance 0.45
Decrease in both Bmax and Kd values of dopamine D1 receptors were observed after naloxone but not morphine treatment in HIPP.
Negative_regulation (Decrease) of D1 in HIPP associated with dopamine, narcan, hippocampus and morphine
6) Confidence 0.04 Published 1995 Journal Pharmacology Section Abstract Doc Link 8584575 Disease Relevance 0.35 Pain Relevance 1.82
These data suggests that the apparent loss of D1 receptors, induced by agonists, may result from an interaction with a guanine-nucleotide sensitive, high affinity agonist binding site and that the degree of interaction with this site depends on the intrinsic D1 activity of the agonist.
Negative_regulation (loss) of D1 associated with agonist
7) Confidence 0.04 Published 1992 Journal Neuropharmacology Section Abstract Doc Link 1532443 Disease Relevance 0 Pain Relevance 0.66
In abstinent rats, both D1- and D2-dopamine receptor mRNA levels were decreased 1 day after withdrawal (-30% compared with chronic morphine).
Negative_regulation (decreased) of D1 associated with dopamine receptor, withdrawal and morphine
8) Confidence 0.03 Published 1999 Journal Eur. J. Neurosci. Section Abstract Doc Link 10051749 Disease Relevance 0.13 Pain Relevance 1.69
D1 agonist-stimulated activity could be inhibited to basal levels with desacetyllevonantradol (1 microM), indicative of D1 and CB1 signal transduction convergence.
Negative_regulation (inhibited) of D1 associated with agonist
9) Confidence 0.03 Published 2001 Journal Neuropharmacology Section Abstract Doc Link 11378162 Disease Relevance 0 Pain Relevance 0.41
We also show that withdrawal is associated with a down regulation of the postsynaptic D1 and D2 receptors.
Negative_regulation (regulation) of D1 associated with withdrawal
10) Confidence 0.03 Published 1999 Journal Eur. J. Neurosci. Section Abstract Doc Link 10051749 Disease Relevance 0.09 Pain Relevance 1.18
These latter results suggest that there is an interaction between D1 and D2 receptors whereby the effects of dopamine mediated via D1 sites are inhibited by an action on D2 sites.
Negative_regulation (inhibited) of D1 associated with dopamine
11) Confidence 0.03 Published 1997 Journal Neuroscience Section Abstract Doc Link 9472401 Disease Relevance 0 Pain Relevance 0.96
OBJECTIVES: The effect of blocking dopamine D1, D2, mu-opiate or delta-opiate receptors in the nucleus accumbens on the intravenous self-administration of combined heroin and cocaine was examined in rats.
Negative_regulation (blocking) of D1 in nucleus accumbens
12) Confidence 0.02 Published 2005 Journal Psychopharmacology (Berl.) Section Body Doc Link 15682301 Disease Relevance 0 Pain Relevance 0
In addition, simultaneous blockade of dopamine D1 and D2 receptors appears necessary to achieve a significant reduction of sensory stimulation-evoked acetylcholine release in the frontal cortex.
Negative_regulation (blockade) of D1 in frontal cortex associated with dopamine and urological neuroanatomy
13) Confidence 0.02 Published 1998 Journal Neuroscience Section Abstract Doc Link 9607704 Disease Relevance 0.09 Pain Relevance 0.48
The excitation, expressed as an increase in both firing rate and bursting, persisted when both D1- and D2-like receptors were blocked by SCH23390 and eticlopride, suggesting that it is not mediated by DA receptors.
Negative_regulation (blocked) of D1 associated with dopamine
14) Confidence 0.02 Published 2000 Journal J. Neurosci. Section Abstract Doc Link 10777813 Disease Relevance 0 Pain Relevance 0.58
Reversible blockade of M1 D1 and D2 receptors temporarily impaired skill acquisition but not execution, and reduced long-term potentiation (LTP) within M1, a form of synaptic plasticity critically involved in skill learning.
Negative_regulation (blockade) of D1 associated with long-term potentiation
15) Confidence 0.01 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2738964 Disease Relevance 0.08 Pain Relevance 0.17
However, stimulating mu-opioid receptors in the ventral tegmental area with [D-Ala2,N-Me-Phe4,Gly-ol5]enkephalin produced a dose-dependent impairment of working memory that was reversed by blocking D1 dopamine receptors with SCH-23390 in the prefrontal cortex.
Negative_regulation (blocking) of D1 in prefrontal associated with ventral tegmentum, dopamine receptor, mu opioid receptor and enkephalin
16) Confidence 0.01 Published 1999 Journal Neuroscience Section Abstract Doc Link 10392833 Disease Relevance 0 Pain Relevance 0.74
The blockade of D1 and/or D2 dopamine receptors with SCH-23390 and sulpiride was without effect on working memory.
Negative_regulation (blockade) of D1 associated with dopamine receptor
17) Confidence 0.01 Published 1999 Journal Neuroscience Section Abstract Doc Link 10392833 Disease Relevance 0 Pain Relevance 0.73
D1 dopamine receptor-mediated substance P depletion in the striatonigral neurons of rats subjected to neonatal dopaminergic denervation: implications for self-injurious behavior.
Negative_regulation (depletion) of D1 in neurons associated with dopamine receptor and substance p
18) Confidence 0.01 Published 1989 Journal Brain Res. Section Title Doc Link 2481560 Disease Relevance 0.16 Pain Relevance 0.65
On the one hand, there is a decrease in dopamine release and D1 receptors' mRNA levels and on the other, an increase in inhibitory dopamine D2 receptors' expression.
Negative_regulation (decrease) of D1 associated with dopamine
19) Confidence 0.01 Published 2010 Journal Mol Pain Section Body Doc Link PMC2994804 Disease Relevance 0.72 Pain Relevance 0.73
These results suggest that the decrease in content of both GAD and PPE mRNA, promoted by the chronic blockade of D1 receptors, is mainly due to the action of dopamine acting on unaffected D2 receptors.
Negative_regulation (blockade) of D1 associated with dopamine and generalized anxiety disorder
20) Confidence 0.01 Published 1991 Journal J. Neurochem. Section Abstract Doc Link 1824860 Disease Relevance 0.51 Pain Relevance 0.37

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox